InvestorsHub Logo
Followers 52
Posts 3335
Boards Moderated 0
Alias Born 10/26/2013

Re: None

Thursday, 05/04/2017 6:08:28 PM

Thursday, May 04, 2017 6:08:28 PM

Post# of 3283
Puma's Senior Vice President, Regulatory Affairs and Project Management will be resigning on May 15th right before the Advisory Committee (ODAC) on May 24th for Neratinib for adjuvant early stage HER2-positive breast cancer That's just plain interesting on so many fronts. Popcorn anyone?

On April 28, 2017, Dr. Robert Charnas, Senior Vice President, Regulatory Affairs and Project Management, notified Puma Biotechnology, Inc. that he will be resigning for health reasons effective May 15, 2017.